A detailed history of Versant Capital Management, Inc transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Versant Capital Management, Inc holds 63 shares of IONS stock, worth $2,542. This represents 0.0% of its overall portfolio holdings.

Number of Shares
63
Previous 55 14.55%
Holding current value
$2,542
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

BUY
$40.06 - $51.86 $320 - $414
8 Added 14.55%
63 $2,000
Q2 2024

Jul 05, 2024

SELL
$36.45 - $47.7 $145 - $190
-4 Reduced 6.78%
55 $2,000
Q4 2023

Jan 08, 2024

SELL
$43.39 - $51.63 $303 - $361
-7 Reduced 10.61%
59 $2,000
Q2 2023

Jul 10, 2023

BUY
$34.73 - $43.33 $138 - $173
4 Added 6.45%
66 $2,000
Q1 2023

Apr 10, 2023

SELL
$33.58 - $41.2 $537 - $659
-16 Reduced 20.51%
62 $2,000
Q1 2022

Apr 29, 2022

BUY
$29.88 - $37.04 $956 - $1,185
32 Added 69.57%
78 $3,000
Q4 2021

Jan 06, 2022

SELL
$25.61 - $35.1 $179 - $245
-7 Reduced 13.21%
46 $1,000
Q3 2021

Oct 29, 2021

BUY
$33.54 - $40.55 $234 - $283
7 Added 15.22%
53 $2,000
Q1 2019

Apr 23, 2019

BUY
$52.92 - $81.17 $2,275 - $3,490
43 Added 1433.33%
46 $3,000
Q1 2019

Apr 23, 2019

SELL
$52.92 - $81.17 $2,275 - $3,490
-43 Reduced 93.48%
3 $3,000
Q2 2018

Jul 06, 2018

SELL
$40.53 - $50.7 $445 - $557
-11 Reduced 19.3%
46 $1,000
Q1 2018

Apr 19, 2018

SELL
$44.08 - $55.05 $5,686 - $7,101
-129 Reduced 69.35%
57 $2,000
Q3 2017

Apr 23, 2018

SELL
$45.56 - $59.57 $1,366 - $1,787
-30 Reduced 13.89%
186 $9,000
Q3 2016

Apr 23, 2018

SELL
N/A
-26 Reduced 10.74%
216 $7,000
Q1 2016

Apr 23, 2018

SELL
N/A
-29 Reduced 10.7%
242 $9,000
Q4 2015

Apr 23, 2018

BUY
N/A
271
271 $16,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.73B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Versant Capital Management, Inc Portfolio

Follow Versant Capital Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Versant Capital Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Versant Capital Management, Inc with notifications on news.